GLP1R and type 2 diabetes mellitus: Given the findings of the CVOTs and recent real-world experience, the use of GLP-1 RAs has now become guideline-recommended by the European Society for Cardiology, American Diabetes Association and European Association for the Study of Diabetes in patients with T2DM and concurrent ASCVD or at high risk of ASCVD, such as those with target organ damage or multiple cardiovascular risk factors [82,83].